(ATCC-9142) [the slant containing as a nutrient medium: glucose (10 g)-yeast extract (2.5 g)- K_2 HPO₄ (1 g)-agar (20 g) in distd H₂O (q.s. to 1 1.)] was suspd in 0.01% aqueous sodium lauryl sulfate. One-milliliter portions of this suspension were used to inoculate three 250-ml erlenmeyer flasks, each containing 50 ml of the following sterilized medium: glucose (30 g)-soy bean meal (20 g)soy bean oil (2.0 g)-CaCO₃ (2.5 g) in distd H_2O (q.s. to 1 l.). After a 96-hr incubation at 25° with continuous rotary agitation (280 cpm; 2-in. stroke), 5% (v/v) transfers were made to 20 250-ml erlenmeyer flasks, each containing 50 ml of the following sterilized medium: corn steep liquor (6 g)- $NH_4H_2PO_4$ (3 g)-yeast extract (2.5 g)-dextrose (10 g)-CaCO₃ (2.5 g) in distd H₂O (q.s. to 1 l.). After 24 hr of further incubation, as described above, 0.25 ml of a sterile soln of 4 in DMF (40 mg/ml) was added. A total of 200 mg (0.00089 mole) was fermented. After 6 days of further incubation as described above, the contents of the flasks were combined, and the broth was adjusted to pH 2.5 with $12 N H_2 SO_4$. The broth was filtd through a Seitz clarifying pad, and the flasks, mycelium, and pad were washed with warm H₂O. The filtrate and washings (1.5 l.) obtained in this way were extd (EtOAc), and the exts were washed (8% aq NaCl), dried, and evapd. Crystn from EtOAc gave 18 (42 mg, mp 235.5–237.5°, mmp, 20%).

7-Hydroxy- α -methylfluorene-2-acetic acid (19) was prepared by reduction of 14 with Zn and CaCl₂ to form 16 (93%), which was diazotized and hydrolyzed as described for the preparation of 18 to give 19 (31%). The analytical sample was prepared by sublimation: mp 218-219°. Anal. (C₁₆H₁₄O₃) C, H. Fermentation of 9 (300 mg, 0.00126 mole) with C. blakesleeana (ATCC 8688a), as described above, gave 19 (98 mg, mp 218-220°, mmp, 30%).

Methyl 7-Hydroxyfluorene-2-acetate (20). Esterification of 18 with CH_2N_2 and crystn from C_6H_6 gave 20 (mp 139–140°, 71%). Anal. ($C_{16}H_{14}O_3$) C, H. Methyl 7-Methoxyfluorene-2-acetate (22). Treatment of 20

Methyl 7-Methoxyfluorene-2-acetate (22). Treatment of 20 with MeI-K₂CO₃ in Me₂CO and crystn from EtOAc-*i*-Pr₂O gave 22 (mp 114.5-115.5°, 65%). Anal. ($C_{17}H_{16}O_{3}$) C, H.

Methyl 7-Methoxy- α -methylfluorene-2-acetate (23). Esterification of 19 with CH₂N₂ and treatment of the ester 21 with MeI-K₂CO₃ in Me₂CO, followed by crystn from Me₂CO-*i*-Pr₂O, gave 23 (mp 101-103°, 44%). Anal. (C₁₈H₁₈O₃) C, H.

7-Methoxyfluorene-2-acetic Acid (24). Hydrolysis of 22 with EtOH-45% aqueous KOH and crystn from EtOH gave 24 (mp 204-205°, 97%). Anal. ($C_{16}H_{14}O_{3}$) C, H.

7-Methoxy-α-methylfluorene-2-acetic Acid (25). Hydrolysis of 23 with EtOH-40% aqueous KOH and crystn from EtOAc gave 25 (mp 183-184°, 80%). Anal. (C₁,H₁₆O₃) C, H. Fluorene-1-acetic Acid (28). Fluorene-1-carboxylic acid was

Fluorene-1-acetic Acid (28). Fluorene-1-carboxylic acid was homologated under the Arndt-Eistert conditions employed in the synthesis of 26 and 27,¹¹ and gave 28 after crystn from EtOH (mp 172-174°, 15%). Anal. ($C_{15}H_{12}O_2$) C, H.

 α -Methylfluorene-1-acetic acid (29) was prepared from fluorene-1-carboxylic acid (3.0 g, 0.014 mole) by Arndt-Eistert homologation¹⁷ with diazoethane.¹⁸ Crystn from MeOH gave 29 (1.4 g, mp 189–191°, 41%). Anal. (C₁₆H₁₄O₂) C, H. α -Methylfluorene-4-acetic acid (30) was prepared, as described for 29, from fluorene-4-carboxylic acid and gave, after sublimation and crystn from MeCN, 30 (mp 176–178°, 62%). Anal. (C₁₆H₁₄O₂) C, H.

 α -Methylfluorene-9-acetic Acid (31). A mixt of 9-bromofluorene (24.5 g, 0.1 mole) and potassium methylmalonic ester [prepared from diethyl methylmalonate (17.2 g) and *tert*-BuOK (11.2 g) in *tert*-BuOH (80 ml)] was refluxed for 4 hr. The mixt was evapd and the residue was dissolved in H₂O and extd (Et₂O). The exts were washed (H₂O), dried, and evaporated. The residue was hydrolyzed with EtOH-40% aqueous KOH to the diacid (2-hr reflux). The diacid was heated at 170-180° until the evolution of CO₂ had ceased. Sublimation of the product gave 31 (3.0 g, mp 103-104°, 13%). Anal. (C₁₆H₁₄O₂) C, H.

Acknowledgments. The authors wish to thank our Immunology Section for the biological results and Mr. J. Alicino and his staff for the microanalyses.

References

- S. S. Adams, E. E. Cliffe, B. Lessel, and J. S. Nicholson, Nature (London), 200, 271 (1963).
- (2) F. D. Hart and P. L. Boardman, Ann. Rheum. Dis., 24, 61 (1965).
- (3) S. S. Adams, E. E. Cliffe, B. Lessel, and J. S. Nicholson, J. Pharm. Sci., 56, 1686 (1967).
- (4) G. Lambelin, J. Roba, C. Gillet, and N. P. Buu-Hoi, Arzneim.-Forsch., 20, 610 (1970).
- (5) I. T. Harrison, B. Lewis, P. Nelson, W. Rooks, A. Roszkowski, A. Tomolonis, and J. H. Fried, J. Med. Chem., 13, 203 (1970).
- (6) G. J. Durant, G. M. Smith, R. G. W. Spickett, and E. Szarvasi, *ibid.*, 8, 598 (1965).
- (7) E. Szarvasi, L. Fontaine, and C. Letourneur, Bull. Soc. Chim. Fr., 3113 (1964).
- (8) J. Redel, H. Brouilhet, N. Brazely, M. Jonanneau, and F. Delbarre, C. R. Acad. Sci., Ser. D, 270, 224 (1970).
- (9) C. A. Winter, E. A. Risley, and G. W. Nuss, Proc. Soc. Exp. Biol. Med., 111, 544 (1962).
- (10) J. von Braun and H. Engel, Chem. Ber., 57, 194 (1924).
- (11) W. E. Bachmann and J. C. Sheehan, J. Amer. Chem. Soc., 62, 2687 (1940).
- (12) J. W. Cook and E. F. M. Stevenson, J. Chem. Soc., 842 (1949).
- (13) Y. Ogata, M. Inoue, and Y. Kitamura, J. Org. Chem., 18, 1329 (1953).
- (14) G. Lock and R. Schneider, Chem. Ber., 88, 564 (1955).
- (15) M. Janczewski and W. Podkoscielny, Rocz. Chem., 34, 1505 (1960).
- (16) M. Dahlgard, I. D. Bokil, and F. E. Ray, J. Org. Chem., 25, 951 (1960).
- (17) A. L. Wilds and A. L. Meader, ibid., 13, 763 (1948).
- (18) A. F. McKay, J. Amer. Chem. Soc., 71, 1968 (1949).


Xanthone-2-carboxylic Acids, a New Series of Antiallergic Substances[†]


J. R. Pfister, R. W. Ferraresi, I. T. Harrison,* W. H. Rooks, A. P. Roszkowski, A. Van Horn, and J. H. Fried

Syntex Research, Stanford Industrial Park, Palo Alto, California 94304. Received April 24, 1972

Substituted xanthone-2-carboxylic acids are shown to be highly active in antiallergic bioassays and are, therefore, of possible value in the treatment of asthma.

We wish to report a new series of antiallergic substances based on xanthone-2-carboxylic acid. It has long been known that khellin (1), a chromone isolated from the fruit and seeds of the plant *Ammi visnaga*, exhibits antiasthma properties of clinical value.¹ Starting from this observation, the Fisons group was able to develop disodium cromoglycate (2), which has become an exceptionally im-





portant agent in the prophylactic treatment of the allergic condition underlying bronchial asthma.^{2,3} Our work

Table I. Physical Properties and Activities in the Iv Rat Passive Cutaneous Anaphylaxis (PCA) Assay of Xanthone-2-carboxylic Acids (Disodium Cromoglycate = 1)

$ \begin{array}{c} 8 \\ 1 \\ 0 \\ R \\ 5 \end{array} $ $ \begin{array}{c} 0 \\ 1 \\ 0 \\ 4 \end{array} $ $ \begin{array}{c} 0 \\ 1 \\ 0 \\ 3 \end{array} $ $ \begin{array}{c} 0 \\ 1 \\ 0 \\ 3 \end{array} $ $ \begin{array}{c} 0 \\ 1 \\ 0 \\ 3 \end{array} $ $ \begin{array}{c} 0 \\ 1 \\ 0 \\ 3 \end{array} $						
Compd	R	Method	Mp, °C	Formula ^a	No. of rats	PCA assay
2 3 ^b	· · · · · · · · · · · · · · · · · · ·	, <u>, , , , , , , , , , , , , , , , , , </u>			.	1 (standard)
30	Н				41	0.5
6	1-CH ₃ O	I	211-213	$C_{15}H_{10}O_{5}$	15	<1
10a	3-CH ₃ O	II	287–288	$C_{15}H_{10}O_{5}$	10	0.3
10Ъ	4-CH ₃ O	II	320-322	$C_{15}H_{10}O_{5}$ $C_{15}H_{10}O_{5}$ $C_{15}H_{10}O_{5}$	10	~0.1
10c	8-CH ₃ O	II	295–297	$C_{15}H_{10}O_{5}$	15	0.4
14a	5-CH ₃ O	III	329-331	$C_{15}H_{10}O_{5}$	60	3
1 4 Ъ	7-CH ₃ O	III	280-281	$\begin{array}{c} C_{15}H_{10}O_{5}^{c}\\ C_{15}H_{10}O_{5}^{d}\end{array}$	94	3
18Ь	6-CH ₂ O	IV	>300	$C_{1}H_{1}O_{1}d$	15	0.3
22a	7-CH ₃	v	300-302	C ₁₅ H ₁₀ O ₄	38	0.5
22b	7-C₂H,́5	v	269-271	C, H, O	45	3
22c	$7 - n - C_3 H_7$	v	254-255	$C_{16}H_{12}O_4$ $C_{17}H_{14}O_4$	29	~1
22d	7- <i>i</i> -C₃H ₇ ′	v	274–276	$C_{17}H_{14}O_{4}$	101	7
22e	7-sec-C ₄ H	v	240	C. H. O.e	30	2
22f	7-n·C₅H ₁₁	V V	242-244	$C_{18}H_{16}O_4^{e}$ $C_{19}H_{18}O_4$	15	< 0.3
22g	5- <i>i</i> -C ₃ H ₇		277-279	C.H.O.	32	~3
22h	7-F	v	>300	$C_{14}H_{14}O_{4}$ $C_{14}H_{7}FO_{4}$	27	~0.2
24	7-OH	VI	>300	$C_{14}H_8O_5$	45	~1
25a	7-C ₂ H ₅ O	VI	287-289	$C_{16}H_{12}O_{5}$	45	1
25b	7-n-C,H,O	VI	263-265	$C_{17}H_{14}O_{5}$	45	ī
25 S	7- <i>i-</i> C ₃ H ₇ O	VI	>300	$C_{17}H_{13}NaO_{5}$	100	8
25d	7-n-C4HO	VI	243-245	CHO.8	50	0.2
25e	5- <i>i</i> -C ₃ H ₇ O	VI	265-266	$C_{18}H_{16}O_{5}g$ $C_{17}H_{14}O_{5}$	45	4
26 ^h	7-CO₂H		>300	$C_{15}H_{8}O_{6}$	58	2

^aAll compds were analyzed for C and H. ^bRef 11. ^cC: calcd, 66.67; found, 66.15. ^dC: calcd, 66.67; found, 66.26. ^eC: calcd, 72.96; found, 72.43. ^fSodium salt. ^gC: calcd, 69.22; found, 69.72. ^hRef 12.


started at this point and was based on our supposition that the OC=CC=O grouping was the major structural parameter responsible for the antiallergy activity of khellin and disodium cromoglycate. Bioassay of a va. riety of compounds containing the OC=CC=O grouping, using the rat passive cutaneous anaphylaxis (PCA) assay with homocytotropic reaginic antibody,⁴ led to the finding of significant antiallergic activity in xanthones and indandiones. Additionally activity was observed with 1,4-naphthaquinones which contain the O=CC=CC=O group. Further work in the xanthone series established that a carboxylic acid substituent at the 2 position was essential for high levels of activity. In this report we describe the relationship of structures to biological activity for these xanthonecarboxylic acids.

The relationship between activity and substitution pattern on the xanthone nucleus was initially determined using the methoxyl substituent. At positions 1, 3, 4, 6, or 8 (Table I, compds 6, 10a, 10b, 18b, and 10c) substitution was accompanied by either a decrease or by little change in activity relative to the unsubstituted xanthone-2-carboxylic acid (3). At the two remaining positions, 5 and 7 (compds 14a and 14b), introduction of the methoxyl group resulted in a sixfold enhancement of activity. Other small alkoxy substituents at the 5 or 7 position, including those with branched chains, also gave more active compounds (25a-c and 25e). A rather similar correlation is evident in the 5- or 7-alkyl-substituted series (22a-g). An unusually wide range of lipophilic-hydrophilic character is tolerated in the substituent group. Thus, *i*-propyl (22d), *i*-propoxy (25c), hydroxyl (24), and carboxyl groups (26) substituted at the 7 position all give highly active compounds.

Further studies have shown that compounds 22c, 22d, 22g, and 25c are active not only by iv and ip routes, but also have marked oral activity. This is of particular sig-

nificance in view of the lack of oral activity observed with disodium cromoglycate which must be administered by inhalation.


The anaphylactic response to the antigen-antibody combination is primarily due to an induced degranulation of mast cells. The resulting release of histamine leads to an increased capillary permeability. Both xanthonecarboxylic acids and disodium cromoglycate⁵ protect mast cells against this degranulation. Thus in a typical experiment $87 \pm 4\%$ (mean \pm se of 8 rats) of the mast cells in the subcutaneous connective tissue from the site of the anaphylactic reaction had degranulated. In similar tissue from nonchallenged control rats $42 \pm 5\%$ of these cells degranulated.




(This control reflects possible damage of the mast cells during tissue preparation.) Compound 25c significantly inhibited mast cell degranulation since only $29 \pm 5\%$ of the mast cells degranulated in challenged rats which were given 0.1 mg of 25c iv. Disodium cromoglycate and the xanthones described here are unique among the known inhibitors of anaphylaxis in their mechanism of action.

Since the work reported above was completed, claims⁶ of antiallergy activity for some substituted xanthone-2-






Scheme III




Scheme IV



carboxylic acids have appeared in the patent literature but quantitative biological data have not been published.

Chemistry. A variety of synthetic schemes were utilized for the preparation of the substituted xanthonecarboxylic acids reported in this study.



Scheme I. 1-Methoxyxanthone-2-carboxylic acid (6) was prepared by Friedel-Crafts acylation⁷ of 1-hydroxyxanthone (4) followed by methylation forming 5 and hypobromite oxidation to the acid 6.

Scheme II. 3-Methoxyxanthone-2-carboxylic acid (10a) was prepared by the coupling⁸ of methyl 2-chlorobenzoate (7a) with the phenol 8a forming the ether 9a, which was saponified and then cyclized⁹ by polyphosphoric acid to the acid 10a. Similarly, 4-methoxyxanthone-2-carboxylic acid (10b) was prepared from the phenol 8b via 9b. 8-Methoxyxanthone-2-carboxylic acid (10c) was prepared from methyl 2-chloro-6-methoxybenzoate (7c) via 9c.

Scheme III. 5-Methoxyxanthone-2-carboxylic acid (14a) was prepared by coupling⁸ 2,4-dimethyliodobenzene (12) with the phenol 11a forming the ether 13a, which was oxidized by KMnO₄ to the dicarboxylic acid 13b and cyclized by polyphosphoric acid or concd H_2SO_4 to the acid 14a. 7-Methoxyxanthone-2-carboxylic acid (14b) was similarly prepared from the phenol 11b via 13c and 13d.

Scheme IV. 6-Methoxyxanthone-2-carboxylic acid (18b) was prepared by methanolysis⁹ of 6-chloroxanthone-2-carboxylic acid (18a).

Scheme V. 5-Alkyl- (22g), 7-alkyl- (22a-f), and 7-fluoro-(22h) substituted xanthone-2-carboxylic acids were prepared by Scheme V, a modification of Scheme III.

Scheme VI. 5-Methoxy- and 7-methoxy-substituted

xanthone-2-carboxylic acids (23) were converted into alkoxyxanthone carboxylic acids (25a-e) by ether cleavage with HBr in acetic acid followed by alkylation of the resulting phenol.

Experimental Section

General Methods. Phenols were coupled with aromatic halides using Cu₂O⁸ in dimethylacetamide (Schemes II, III, and V) and copper powder¹⁰ with anhydrous potassium carbonate in dimethylformamide (Scheme IV). Dicarboxylic acids were cyclized to xanthonecarboxylic acids by polyphosphoric acid⁹ in tetramethylene sulfone or with concd H_2SO_4 . Methyl diphenyl ethers were oxidized to the corresponding diphenylcarboxylic acids by KMnO₄ in tert-BuOH-H₂O. Methanolysis of 6-chloroxanthone-2-carboxylic acid (18a) was performed as described by Goldberg and Wragg,⁹ except that HMPA was used as solvent.

Acknowledgments. The authors wish to thank Denis J. Kertesz for the preparation of 10c, Ernest Kepel, Wanda Sheehan, Nancy A. Sutter, Janet T. Imagawa, and Margery E. Schuler for the biological data, and Dr. Howard Ringold for helpful comments.

References

- (1) C. P. Huttrer and E. Dale, Chem. Rev., 48, 543 (1951).
- (2) J. S. G. Cox, Nature (London), 216, 1328 (1967).
- (3) H. Cairns, C. Fitzmaurice, D. Hunter, P. B. Johnson, J. King, T. B. Lee, G. H. Lord, R. Minshull, and J. S. G. Cox, J. Med. Chem., 15, 583 (1972).
- (4) I. Mota, *Immunology*, 7, 681 (1964).
 (5) G. Goose and A. M. J. N. Blair, *ibid.*, 16, 749 (1969).
- (6) Allen and Hanburys Limited, Belgian Patent 759,292 (1971). (7) J. S. H. Davies, F. Scheimmann, and H. Suschitzky, J. Chem.
- Soc., 2140 (1956).
- (8) R. J. R. Bacon and O. J. Stewart, ibid., 4953 (1965).
- (9) A. A. Goldberg and A. H. Wragg, ibid., 4227 (1958).
- (10) H. Meerwein in "Methoden Der Organischen Chemie," Vol. 6, Part 3, Verlag, Stuttgart.
- (11) A. M. El-Abbady, S. Ayoub, and F. G. Baddar, J. Chem. Soc., 2556 (1960).
- (12) T. Sengoku, Yakugaku Zasshi, 53, 962 (1933).


Antiparasitic Nitroimidazoles. 1. Some 2-Styryl-5-nitroimidazoles

William J. Ross,* William B. Jamieson, and Max C. McCowen

Lilly Research Centre Ltd., Erl Wood Manor, Windlesham, Surrey, England. Received March 22, 1972

A series of 1-substituted-2-styryl-5-nitroimidazoles was prepared by condensing 1-substituted-2-methyl-5-nitroimidazoles with aryl aldehydes in the presence of sodium methoxide. The aryl aldehydes were substituted with aryl, alkyl, alkoxyl, and chloro groups while the 1 substituent on the imidazole nucleus varied from alkyl to hydroxyalkyl to alkylene. The alkylene substituent was introduced by base elimination of the tosylates of the hydroxyalkyl compounds. A number of arylethynyleneimidazoles were also prepared by bromination of the styryl compound followed by didehydrobromination with DBN. All the compounds were tested against Trichomonas vaginalis and Entamoeba histolytica in vitro and in vivo and against various Trypanosoma species in vivo. Structure-activity relationships are discussed and comparisons of biological activity made with established drugs.


Since the discovery of the antibacterial and antiprotozoal activity of the antibiotic azomycin, 1, 1^{-3} and the subsequent introduction of metronidazole,⁴ 2, as a clinically effective trichomonicide, many papers⁵ have appeared on the biological properties of nitroimidazoles.



Although several papers and patents⁶⁻⁸ have described the preparation of styrylimidazoles and their antitrichomonal and antiamoebic properties in vitro none of the compounds so far discussed appear to have in vivo activity against these protozoa. In an early paper, Ellis, et al., 6 described the preparation of 3a and its in vitro activity against Trichomonas vaginalis but no in vivo activity was reported. Similarly, during the course of our work, Giraldi and his coworkers⁷ described a series of styrylimidazoles, exemplified by 3b and 4, which, although very active against T. vaginalis and Entamoeba histolytica in vitro, were devoid of in vivo activity.


In this paper we describe a series of 2-styryl-5-nitroimidazoles which exhibit a wide range of antiprotozoal activity both in vitro and in vivo against T. vaginalis, E. histolytica, and various Trypanosoma species.

Chemistry. The 2-styryl-5-nitroimidazoles were all prepared by the general route shown in Scheme I followed by modification of the N substituent in appropriate cases.



The N-vinyl series (Table IV) could be prepared by condensing the aromatic aldehyde with 5 ($R = CH = CH_2$) or by base elimination of the tosylate derived from 6 (R =CH₂CH₂OH).

In general, it was better to prepare the N-vinyl series by the latter method because compounds of type 6 (R = vinyl)Scheme I



R = alkyl, hydroxylalkyl, or vinyl